Subscribe to RSS
DOI: 10.1055/s-2001-15451
Hypericum Extract and Hyperforin:
Memory-Enhancing Properties in Rodents
Publication History
Publication Date:
31 December 2001 (online)
![](https://www.thieme-connect.de/media/pharmaco/2001Sup1/lookinside/thumbnails/10.1055-s-2001-15451-1.jpg)
Effects of a Hypericum extract in therapeutic use and hyperforin sodium salt were evaluated in rat and mouse avoidance tests. In a conditioned avoidance response (CAR) test on the rat, oral daily administration of hyperforin (1.25 mg/kg/day) or of the extract (50 mg/kg/day) before the training sessions considerably improved learning ability from the second day onwards until the day 7. In addition, the memory of the learned responses acquired during 7 consecutive days of administration and training was largely retained even after 9 days without further treatment or training. The observations made using different doses indicate that these learning-facilitating and/or memory-consolidating effects by the agents follow inverse U-shaped dose-response curves in dose ranges lower than (for hyperforin) or equal to (for Hypericum extract) their effective dose in the behavioral despair test for antidepressants. In a passive avoidance response test on the mouse, a single oral dose (1.25 mg/kg) of hyperforin not only improved memory acquisition and consolidation, but also almost completely reversed scopolamine-induced amnesia. The single Hypericum extract dose tested (25 mg/kg) did not reveal any significant effects in the passive avoidance response (PAR) test on the mouse. These observations suggest that the Hypericum extract could be a novel type of antidepressant with memory enhancing properties, and indicate that hyperforin is involved in its cognitive effects. Pure hyperforin seems to be a more potent antidementia agent than an antidepressant.
References
- 1 Bassuk S S, Berkman L F, Wypij D. Depressive symptomatology and incident cognitive decline in an elderly community sample. Arch Gen Psychiat. 1998; 55 1073-1081
- 2 Bhattacharya S K, Chakrabarti A, Chatterjee S S. Activity profiles of two hyperforin-containing hypericum extracts in behavioral models. Pharmacopsychiatry. 1998; 31 (Suppl 1) 22-29
- 3 Biber A, Fischer H, Römer A, Chatterjee S S. Oral bioavailability of hyperforin from hypericum extracts in rat and human volunteers. Pharmacopsychiatry. 1998; 31 (Suppl 1) 36-43
- 4 Boone K B, Lesser I, Miller B, Wohl M, Berman N, Lee A, Palmer B. Cognitive functioning in a mildly to moderately depressed geriatric sample: Relationship to chronological age. J. Neuropsychiat. Clin Neurosci. 1994; 6 267-272
- 5 Butterweck V, Wall A, Liefländer-Wulf U, Winterhoff H, Nahrstedt A. Effects of the total extract and fractions of hypericum perforatum in animal assays for antidepressant activity. Pharmacopsychiatry. 1997; 30 (Suppl 2) 117-124
- 6 Butterweck V, Petereit F, Winterhoff H, Nahrstedt A. Solubilized hypericin and pseudohypericin from hypericum perforatum exert antidepressant activity in the forced swimming test. Planta Med. 1998; 64 291-294
- 7 Butterweck V, Jürgenliemk G, Nahrstedt A, Winterhoff H. Flavonoids from Hypericum perforatum show antidepressant activity in the forced swimming test. Planta Med. 2000; 66 3-6
- 8 Chatterjee S S, Koch E, Nöldner M, Biber A, Erdelmeier C. Hyperforin and hypericum extract: Interactions with some neurotransmitter systems. Phytomedicine. 1999; 3 ( Suppl 1) 106
- 9 Chatterjee S S, Nöldner M, Koch E, Erdelmeier C. Antidepressant activity of Hypericum perforatum and Hyperforin: the neglected possibility. Pharmacopsychiat. 1998; 31 ( Suppl 1) 7-15
- 10 Chatterjee S S, Bhattacharya S K, Wonnemann M, Singer A, Müller W E. Hyperforin as a possible antidepressant component of hypericum extracts. Life Sci. 1998a; 63 499-510
- 11 Chatterjee S S, Erdelmeier C, Klessing K, Marmé D, Schächtele C. Stable hyperforin salts, method for producing same and their use in the treatment of Alzheimer's disease. PCT WO 99/41220 1999
- 12 Czygan F C. Kulturgeschichte und Mystik des Johanniskrautes. Zeitschrift für Phytotherapie. 1993; 14 276-282
- 13 Daniel K. Johanniskraut (Hypericum perforatum) bei psychischen Störungen. Hippokrates. 1935; 10 929-932
- 14 DeWied D, Bohus B. Long term and short term effects on retention of conditioned avoidance response in rats by treatment with long acting pitressin and α-MSH. Nature. 1966; 212 98-100
- 15 Evenhuis H M. The natural history of dementia in ageing people with intellectual disability. J Intellect Disability Res. 1997; 41 92-96
- 16 Gaster B, Holroyd J. St. John's Wort for depression - A systematic review. Arch. Intern Med. 2000; 160 152-156
- 17 Johnson D, Siebenhüner G, Hofer E, Sauerwein-Giese E, Frauendorf A. Einfluß von Johanniskraut auf die ZNS-Aktivität. TW Neurol Psychiatr. 1992; 6 436-444
- 18 Johnson D, Ksciuk H, Woelk H, Sauerwein-Giese E, Frauendorf A. Effects of hypericum extract LI 160 compared with maprotiline on resting EEG and evoked potentials in 24 volunteers. J Ger Psychiat Neurol. 1994; 7 (Suppl 1) S 44-S 46
- 19 Kokmen E, Beard C M, Chandra C, Offord K B, Schoenberg B S, Ballard D J. Clinical risk factors for Alzheimer's disease: a population-based case-control study. Neurology. 1991; 41 1393-1397
- 20 Laakmann G, Schüle C, Baghai T, Kieser M. St. John's Wort in mild to moderate depression: The relevance of Hyperforin for clinical efficacy. Pharmacopsychiatry. 1998; 31 (Suppl 1) 54-59
- 21 Lehrl S, Willemsen A, Papp R, Woelk H. Ergebnisse von Messungen der kognitiven Leistungsfähigkeit bei Patienten unter der Therapie mit Johanniskraut-Extrakt. Nervenheilkunde. 1993; 12 281-284
- 22 Linde K, Ramirez G, Mulrow C D, Pauls A, Weidenhammer W, Melchart D. St. John's Wort for depression - an overview and meta-analysis of randomized clinical trials. Brit Med J. 1996; 313 253-258
- 23 Maisenbacher P, Kovar K A. Analysis and stability of hyperici-oleum. Planta Med. 1992; 58 351-354
-
24 McGaugh J L, Liang D C, Bennet C, Sternberg D B.
Adrenergic influences on memory storage interaction of peripheral and central systems. In: Lynch G. (Ed.) Neurobiology of learning and memory. Guilford Press, New York 1984 - 25 Mitchell A J. The contribution of hypercortisolaemia to the cognitive decline of geriatric depression. Int J Ger Psychiat. 1995; 10 401-409
- 26 Mitchell A J, Dening T R. Depression-related cognitive impairment: Possibilities for its pharmacological treatment. J Affect Disord. 1996; 36 79-87
- 27 Müller W E, Rolli A, Schäfer C, Hafner U. Effects of hypericum extract (LI 160) in biochemical models of antidepressant activity. Pharmacopsychiatry. 1997; 30 (Suppl 2) 102-107
- 28 Müller W E, Kasper S. Editors of: “Hypericum extract (LI 160) as a herbal antidepressant”. Pharmacopsychiatry. 1997; 30 (Suppl 2) 71-134
- 29 Müller W E, Singer A, Wonnemann M, Hafner U, Rolli M, Schäfer C. Hyperforin represents the neurotransmitter reuptake inhibiting constituent of hypericum extract. Pharmacopsychiatry. 1998; 30 (Suppl 1) 16-21
- 30 Müller W E, Chatterjee S S. Editors of: “Hyperforin and the antidepressant activity of St. John's Wort.” Pharmacopsychiatry. 1998; 31 (Suppl 1) 1-60
- 31 Nöldner M, Chatterjee S S, Erdelmeier C. Pharmacological studies leading to the identification of hyperforin as a CNS-Active component of Hypericum perforatum. Naunyn-Schm Arch Pharmacol. 1998; 358 R 495
- 32 Okpanyi S N, Weischer M L. Tierexperimentelle Untersuchungen zur psychotropen Wirksamkeit eines Hypericum-Extraktes. Arzneim-Forsch. 1987; 37 (I) 10-13
- 33 Palsson S, Aevarsson O, Skoog I. Depression, cerebral atrophy, cognitive performance and incidence of dementia - population study of 85-year-olds. Br J Psychiat. 1999 ; 174 249-253
- 34 Popoli M, Brunello N, Perez J, Racagni G. Second messenger-regulated protein kinases in the brain: Their functional role and the action of antidepressant drugs. J Neurochem. 2000; 74 21-33
- 35 Reh C, Laux P, Schenk N. Hypericum-Extrakt bei Depressionen - eine wirksame Alternative. Therapiewoche. 1992; 42 1576-1581
- 36 Sandler M. Forty years in conceptual wilderness. Science. 1998; 280 1709-1710
- 37 Schulz V. Johanniskraut als pflanzliches Antidepressivum. Phytopharmaka in Forschung und klinischer Anwendung. In: Eds. Loew D. and Rietbrock N. Steinkopff Darmstadt 1995: 159-175
- 38 Singer A, Wonnemann M, Müller W E. Hyperforin, a major antidepressant constituent of St. John's Wort, inhibits serotonin uptake by elevating free intracellular Na + 1 . J Pharmacol Exptl Therap. 1999; 290 1363-1368
- 39 Steffens D C, Plassmann B L, Helms M J, Welsh-Bohmer K A, Saunders A M, Breitner J CS. A twin study of late-onset depression and apolipoprotein E ε 4 as risk factors for Alzheimer's disease. Biol Psychiat. 1997; 41 851-856
- 40 Suzuki O, Katsumata Y, Oya M, Bladt S, Wagner H. Inhibition of monoamine oxidase by hypericin. Planta Med. 1984; 3 273-276
- 41 Volz H P. Controlled clinical trials of hypericum extracts in depressed patients: An overview. Pharmacopsychiatry. 1997; 30 ((Suppl. 2)) 72-76
- 42 Vorbach E U, Arnoldt K H, Wolpert E. St. John's Wort: A potential therapy for elderly depressive patients?. Drugs and Aging. 2000; 16 189-197
- 43 Wonnemann M, Singer A, Müller W E. Inhibition of synaptosomal uptake of 3H-L-glutamate and 3H-GABA by hyperforin, a major constituent of St. John's Wort: The role of amiloride sensitive sodium conductive pathways. Neuropsychopharmacol. 2000; 23 188-197
Dr. V. Klusa
University of Latvia
Faculty of Medicine
Sarlotes st. 1A
LV-1001 Riga
Latvia
Email: vijaklus@acad.latnet.lv